SMARCB1 and gastrointestinal stromal tumor: In the past few years, scientific progress in the complex field of STS has mainly been driven by the identification and implementation of novel prognostic and predictive markers, as illustrated by the success of kinase inhibitors treatments for gastrointestinal stromal tumors (GIST) [3], the use of epigenetic modifiers for epithelioid sarcomas with integrase interactor 1 loss [4], or the agnostic use of neurotrophic receptor tyrosine kinase (NTRK) inhibitors in sarcomas with specific gene fusions [5].